NCT06226545: An ongoing trial by Lassen Therapeutics Inc.
This trial is ongoing. It must report results 4 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06226545 |
|---|---|
| Title | A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 5, 2024 |
| Completion date | April 22, 2025 |
| Required reporting date | April 22, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |